A Phase 2 study of AKCEA-ANGPTL3-LRx in patients with familial partial lipodystrophy

Trial Profile

A Phase 2 study of AKCEA-ANGPTL3-LRx in patients with familial partial lipodystrophy

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs IONIS ANGPTL3 LRx (Primary)
  • Indications Lipodystrophy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 17 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top